These updates are republished press releases and communications from members of the Science|Business Network COVID-19 research at Institut Pasteur makes progress thanks to EIB Group donation Developing diagnostic and serological tests as well as vaccine strategies for preventing SARS-CoV-2 infection have been the areas that have benefited from an EIB Group donation to Institut Pasteur, in France. Since the beginning of 2020, Institut Pasteur has been working on several vaccines for SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Three of the vaccines are already well advanced. Two use viral vectors and the third one is a DNA vaccine. Institut Pasteur has also used the funding for modelling, epidemiology and dynamics of immune responses, the biology of SARS-CoV-2, virus-host interactions and therapeutic strategies for treating or preventing SARS-CoV-2 infection. Click here for more information.